Scholarlink

Purpose <p>This study aims to evaluate the clinical features, prognosis, and complications of 20 cases diagnosed with cytomegalovirus anterior uveitis anterior uveitis (CMV AU) who used oral valganciclovir (VGV).</p> Methods <p>The medical records of patients with CMV AU were reviewed and patients underwent complete ophthalmologic examinations.</p> Results <p>Six patients (30%) were female and 14 patients (70%) were male. The mean age of admission to the Uvea-Behçet unit was 41.0 ± 3.2&#xa0;years (range, 19–66&#xa0;years). Acute type CMV AU was diagnosed in six (30%) patients and chronic type AU was diagnosed in 14 (70%) patients. CMV-associated AU was divided into two types: acute (Posner type) and chronic. The chronic type was further categorized into two groups: Fuchs type and chronic mixed type. The acute type was diagnosed in six patients (30%) and the chronic type was diagnosed in 14 patients (70%); The acute type was diagnosed in six patients (30%) and the chronic type in 14 patients (70%); two patients (10%) of the chronic type were diagnosed with Fuchs and 12 patients (60%) with chronic mixed type. The mean intraocular pressure (IOP) before treatment was 36.4 ± 19.5&#xa0;mm Hg (13–75&#xa0;mm Hg). The pupils of the patients remained round, and vitritis, prominent posterior synechiae, and heterochromia did not present in any patients. Mild diffuse iris stromal atrophy was seen in four patients (20%). The average duration of oral VGV treatment was 13.4 ± 1.3&#xa0;months (range, 6–25&#xa0;months). No recurrence was observed in 12 patients (60%) monitored for remission after oral VGV treatment was stopped. The average duration of remission for these 12 patients (60%) was 36.1 ± 8.2&#xa0;months (range, 18–102&#xa0;months). The mean IOP level after treatment was 9.9 ± 3.3&#xa0;mm Hg (range, 7–15&#xa0;mm Hg). Two patients (10%) underwent Ahmed glaucoma valve surgery since their IOP levels did not reduce despite their uveitis inflammation remaining in remission.</p> Conclusions <p>Oral VGV therapy is an effective and safe treatment for CMV AU. Effective prevention against glaucoma involves early detection of CMV AU and prompt access to oral VGV treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical characteristics and outcomes of twenty patients with cytomegalovirus-associated anterior uveitis treated with valganciclovir

  • 期刊论文

  • 发表日期：

    2025年12月16日

查看全文
  • Gülten Sungur,
  • Gözde Orman,
  • Nurten Ünlü,
  • Ayşe Burcu

摘要

Purpose

This study aims to evaluate the clinical features, prognosis, and complications of 20 cases diagnosed with cytomegalovirus anterior uveitis anterior uveitis (CMV AU) who used oral valganciclovir (VGV).

Methods

The medical records of patients with CMV AU were reviewed and patients underwent complete ophthalmologic examinations.

Results

Six patients (30%) were female and 14 patients (70%) were male. The mean age of admission to the Uvea-Behçet unit was 41.0 ± 3.2 years (range, 19–66 years). Acute type CMV AU was diagnosed in six (30%) patients and chronic type AU was diagnosed in 14 (70%) patients. CMV-associated AU was divided into two types: acute (Posner type) and chronic. The chronic type was further categorized into two groups: Fuchs type and chronic mixed type. The acute type was diagnosed in six patients (30%) and the chronic type was diagnosed in 14 patients (70%); The acute type was diagnosed in six patients (30%) and the chronic type in 14 patients (70%); two patients (10%) of the chronic type were diagnosed with Fuchs and 12 patients (60%) with chronic mixed type. The mean intraocular pressure (IOP) before treatment was 36.4 ± 19.5 mm Hg (13–75 mm Hg). The pupils of the patients remained round, and vitritis, prominent posterior synechiae, and heterochromia did not present in any patients. Mild diffuse iris stromal atrophy was seen in four patients (20%). The average duration of oral VGV treatment was 13.4 ± 1.3 months (range, 6–25 months). No recurrence was observed in 12 patients (60%) monitored for remission after oral VGV treatment was stopped. The average duration of remission for these 12 patients (60%) was 36.1 ± 8.2 months (range, 18–102 months). The mean IOP level after treatment was 9.9 ± 3.3 mm Hg (range, 7–15 mm Hg). Two patients (10%) underwent Ahmed glaucoma valve surgery since their IOP levels did not reduce despite their uveitis inflammation remaining in remission.

Conclusions

Oral VGV therapy is an effective and safe treatment for CMV AU. Effective prevention against glaucoma involves early detection of CMV AU and prompt access to oral VGV treatment.